Sökning: WFRF:(Olsson Gunnar) > Successful mobiliza...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07119naa a2201009 4500 | |
001 | oai:DiVA.org:oru-12052 | |
003 | SwePub | |
008 | 101005s2006 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:umu-16148 | |
009 | oai:DiVA.org:uu-95820 | |
009 | oai:prod.swepub.kib.ki.se:1940578 | |
009 | oai:lup.lub.lu.se:8ceed374-7265-4c40-8d7e-00900d6c6c09 | |
009 | oai:DiVA.org:liu-37789 | |
009 | oai:DiVA.org:oru-22582 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-120522 URI |
024 | 7 | a https://doi.org/10.1080/104281906006111172 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-161482 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-958202 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:19405782 URI |
024 | 7 | a https://lup.lub.lu.se/record/3786982 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-377892 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-225822 URI |
040 | a (SwePub)orud (SwePub)umud (SwePub)uud (SwePub)kid (SwePub)lud (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Olsson-Strömberg, Ullau Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi4 aut |
245 | 1 0 | a Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase |
264 | c 2009-07 | |
264 | 1 | b Informa UK Limited,c 2006 |
338 | a print2 rdacarrier | |
520 | a The aim of the study was to investigate the feasibility of mobilizing Philadelphia chromosome negative (Ph-) blood stem cells (BSC) with intensive chemotherapy and lenograstim (G-CSF) in patients with CML in first chronic phase (CP1). During 1994-1999 12 centers included 37 patients <56 years. All patients received 6 months' IFN, stopping at median 36 (1-290) days prior to the mobilization chemotherapy. All received one cycle of daunorubicin 50 mg/m2 and 1 hour infusion on days 1-3, and cytarabine (ara-C) 200 mg/m2 24 hours' i.v. infusion on days 1-7 (DA) followed by G-CSF 526 microg s.c. once daily from day 8 after the start of chemotherapy. Leukaphereses were initiated when the number of CD 34+ cells was >5/microl blood. Patients mobilizing poorly could receive a 4-day cycle of chemotherapy with mitoxantrone 12 mg/m2/day and 1 hour i.v infusion, etoposide 100 mg/m2/day and 1 hour i.v. infusion and ara-C 1 g/m2/twice a day with 2 hours' i.v infusion (MEA) or a second DA, followed by G-CSF 526 microg s.c once daily from day 8 after the start of chemotherapy. Twenty-seven patients received one cycle of chemotherapy and G-CSF, whereas 10 were mobilized twice. Twenty-three patients (62%) were successfully (MNC >3.5 x 10(8)/kg, CFU-GM >1.0 x 10(4)/kg, CD34+ cells >2.0 x 10(6)/kg and no Ph+ cells in the apheresis product) [n = 16] or partially successfully (as defined above but 1-34% Ph+ cells in the apheresis product) [n = 7] mobilized. There was no mortality during the mobilization procedure. Twenty-one/23 patients subsequently underwent auto-SCT. The time with PMN <0.5 x 10(9)/l was 10 (range 7-49) and with platelets <20 x 10(9)/l was also 10 (2-173) days. There was no transplant related mortality. The estimated 5-year overall survival after auto-SCT was 68% (95% CI 47 - 90%), with a median follow-up time of 5.2 years.We conclude that in a significant proportion of patients with CML in CP 1, intensive chemotherapy combined with G-CSF mobilizes Ph- BSC sufficient for use in auto-SCT. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
653 | a MEDICINE | |
653 | a MEDICIN | |
653 | a Oncology | |
653 | a Onkologi | |
653 | a Onkologi | |
653 | a Oncology | |
653 | a CML | |
653 | a G-CSF | |
653 | a autologous transplantation | |
653 | a CML | |
653 | a stem cell mobilization | |
653 | a Medicin | |
700 | 1 | a Höglund, Martinu Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi4 aut |
700 | 1 | a Björkholm, Magnusu Karolinska Institutet4 aut |
700 | 1 | a Braide, Inger4 aut |
700 | 1 | a Carlson, Karin4 aut |
700 | 1 | a Gahrton, Göstau Karolinska Institutet4 aut |
700 | 1 | a Grimfors, Gunnar4 aut |
700 | 1 | a Hast, Robertu Karolinska Institutet4 aut |
700 | 1 | a Lerner, Rickard4 aut |
700 | 1 | a Linder, Olle4 aut |
700 | 1 | a Ljungman, Peru Karolinska Institutet4 aut |
700 | 1 | a Löfvenberg, Eva4 aut |
700 | 1 | a Malm, Claes,d 1945-u Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Hematologiska kliniken US4 aut0 (Swepub:liu)clama59 |
700 | 1 | a Nilsson, Per-Gunnaru Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine4 aut0 (Swepub:lu)med-pni |
700 | 1 | a Paul, Christeru Karolinska Institutet4 aut |
700 | 1 | a Rödjer, Stig4 aut |
700 | 1 | a Stenke, Leifu Karolinska Institutet4 aut |
700 | 1 | a Tidefelt, Ulfu Örebro universitet,Institutionen för klinisk medicin4 aut0 (Swepub:oru)uftt |
700 | 1 | a Turesson, Ingemar4 aut |
700 | 1 | a Udén, Ann-Marie4 aut |
700 | 1 | a Wahlin, Andersu Umeå universitet,Institutionen för folkhälsa och klinisk medicin4 aut0 (Swepub:umu)anwa0027 |
700 | 1 | a Vilén, Lars4 aut |
700 | 1 | a Winqvist, Ingemar4 aut |
700 | 1 | a Zettervall, Olle4 aut |
700 | 1 | a Öberg, Gunnaru Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi4 aut |
700 | 1 | a Simonsson, Bengtu Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi4 aut |
700 | 1 | a Winqvist, Gunnar4 aut |
710 | 2 | a Uppsala universitetb Institutionen för medicinska vetenskaper4 org |
773 | 0 | t Leukemia and Lymphomad : Informa UK Limitedg 47:9, s. 1768-73q 47:9<1768-1773x 1042-8194x 1029-2403 |
773 | 0 | t Leuk Lymphomad : Informa UK Limitedg 47:9, s. 1768-73q 47:9<1768-73 |
856 | 4 | u http://dx.doi.org/10.1080/10428190600611117y FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-12052 |
856 | 4 8 | u https://doi.org/10.1080/10428190600611117 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-16148 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-95820 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:1940578 |
856 | 4 8 | u https://lup.lub.lu.se/record/378698 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-37789 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-22582 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.